These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1564 related articles for article (PubMed ID: 36248822)
1. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R Front Immunol; 2022; 13():990790. PubMed ID: 36248822 [TBL] [Abstract][Full Text] [Related]
2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
4. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Liu Y; Jiang J Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878 [TBL] [Abstract][Full Text] [Related]
5. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma. Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032 [TBL] [Abstract][Full Text] [Related]
7. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. Liu R; Liu Y; Zhang F; Wei J; Wu L Front Immunol; 2023; 14():1146411. PubMed ID: 37063920 [TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
9. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. Chen X; Hu G; Xiong L; Xu Q Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162 [No Abstract] [Full Text] [Related]
10. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy. Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S Front Immunol; 2022; 13():945516. PubMed ID: 36248857 [TBL] [Abstract][Full Text] [Related]
11. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma. Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831 [TBL] [Abstract][Full Text] [Related]
12. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma. Wang L; Yao B; Yang J; Tian Z; He J BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684 [TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. Zhang Z; Zeng X; Wu Y; Liu Y; Zhang X; Song Z Front Immunol; 2022; 13():925618. PubMed ID: 35898502 [TBL] [Abstract][Full Text] [Related]
14. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
15. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma. Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma. Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H Front Immunol; 2022; 13():991604. PubMed ID: 36685508 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J Front Genet; 2023; 14():1094793. PubMed ID: 36891150 [No Abstract] [Full Text] [Related]
18. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features. Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090 [TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients. Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738 [TBL] [Abstract][Full Text] [Related]
20. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma. Li Y; Zeng X Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728 [No Abstract] [Full Text] [Related] [Next] [New Search]